This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
Biogen Idec Inc. (BIIB - Analyst Report) and partner Elan Corporation (ELN - Snapshot Report) recently submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking to update the label of their multiple sclerosis (MS) drugTysabri (natalizumab).
The companies are looking to get Tysabri approved as a first line treatment for patients suffering from certain relapsing forms of multiple sclerosis (MS) who have tested negative for antibodies to the JC virus (JCV).
The application is based on risk stratification data. Tysabri slows disability progression by 42% – 54% and reduces annualized relapse rates by 68%.
Tysabri is the primary growth driver at Elan. As per Elan, Tysabri global net sales in the third quarter of 2012 rose 9.8% to $306.4 million. However, third quarter 2012 Tysabri revenues at Biogen declined 1% to $275 million.
We note that Tysabri is approved in the US for treating relapsing forms of multiple sclerosis (MS) in patients who show inadequate response to or are unable to tolerate other treatments. In the EU, Tysabri is approved for treating highly active relapsing-remitting MS (RRMS) in adults who have severe RRMS or have not responded to beta interferon treatment.
In the EU, Tysabri was approved in 2006 and in the US it was initially approved in 2004. The product was withdrawn from US markets in 2005 due to the progressive multifocal leukoencephalopathy (PML) concern. The drug was reintroduced by Biogen and Elan after a year with a strict warning regarding the occurrence of PML.
We currently have a Neutral recommendation on both Biogen and Elan. While Biogen carries a Zacks Rank #3 (Hold) in the short run, Elan carries a Zacks Rank #2 (Buy). Right now Valeant Pharmaceuticals (VRX - Snapshot Report) looks more attractive with a Zacks Rank #1 (Strong Buy).
Please login to Zacks.com or register to post a comment.